Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7033877+ Bronchoscopy · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7033877 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| RO7033877 + Bronchoscopy | DRUG | Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3. |
Inclusion Criteria: * Male or female healthy volunteers, 18 to 55 years of age, inclusive. A female participant is eligible to participate if she is of non-childbearing potential defined as postmenopausal or surgically sterile * Healthy status is defined by absence of evidence of any active or chro...
RO7033877 is an investigational small molecule being studied in healthy volunteers. A completed Phase 1 trial evaluated its penetration into the lung. It is not approved for any indication and remains in clinical development.
RO7033877 is being developed by Roche Holding AG, traded on the OTC market under the ticker RHHBY. The company conducted a Phase 1 study of the drug in healthy volunteers in the United States.
RO7033877 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug is investigational and has not been approved by regulatory authorities.
RO7033877 was studied in a single completed Phase 1 trial, NCT02165293, titled 'A Single Center Study to Evaluate the Penetration of RO7033877 Into the Lung in Healthy Volunteers.' The trial enrolled 32 participants in the United States and was not blinded or controlled.
RO7033877 is sometimes referred to as RO7033877+ Bronchoscopy, which reflects the bronchoscopy procedure used in the clinical trial to measure lung penetration. The drug itself is a small molecule, and the trial involved healthy volunteers aged 18 years and older.